The History of N-Acetylcysteine: From Mucolytic to Antidote and Beyond

Few molecules have had as varied a career as N-acetylcysteine, usually shortened to NAC. It began life as a medicine for thick, sticky mucus, became one of the most important antidotes in emergency medicine, and has since been studied in conditions ranging from kidney injury to addiction. Our editorial team traces how a simple derivative of an amino acid earned such a broad reputation, and where the hype has run ahead of the evidence.

A modified amino acid with a sulphur key

N-acetylcysteine is the acetylated form of cysteine, one of the sulphur-containing amino acids found in ordinary dietary protein. Adding an acetyl group to the nitrogen atom makes the molecule more stable than free cysteine, which oxidises readily in solution. That small chemical tweak turned out to be decisive for its use as a medicine.

The most important feature of NAC is its free thiol group, the sulphur–hydrogen pair often written as –SH. Thiols can break disulphide bridges, the chemical cross-links that hold some proteins in a rigid shape. They can also donate electrons, which is why NAC is frequently described as an antioxidant, although its direct antioxidant activity in the body is modest.

Its main biological role is indirect. Once absorbed and deacetylated, NAC supplies cysteine, which is usually the limiting building block for glutathione. Glutathione is the body's principal intracellular antioxidant and a central player in detoxifying reactive compounds in the liver. Almost every chapter of NAC's history comes back to this link.

Oral NAC has low bioavailability, often quoted in pharmacology reviews at well under a fifth of the dose, because much of it is metabolised in the gut wall and liver on first pass. For the uses described below, that limitation shaped how the drug is given: inhaled for the lungs, intravenously in poisoning, and orally where high doses are acceptable.

The 1960s: a medicine for mucus

NAC entered clinical medicine in the early 1960s as a mucolytic, a substance that thins bronchial secretions. Researchers had noticed that thiol compounds could liquefy mucus in the laboratory by severing the disulphide bonds that link mucin glycoproteins into a thick gel. NAC was more practical than earlier thiols because it was relatively stable and tolerable.

In the United States it was approved in 1963 as an inhaled solution for patients with chronic bronchitis, cystic fibrosis and other conditions involving viscous sputum. Over the following decades, oral and effervescent preparations became common across continental Europe, where acetylcysteine is still widely sold for productive coughs.

Its reputation in respiratory medicine has always been mixed. Inhaled NAC can irritate the airways and provoke bronchospasm in sensitive people, which limited its use in asthma. Oral formulations have been studied for decades in chronic obstructive pulmonary disease, with some trials suggesting fewer exacerbations at higher doses and others showing little benefit.

In the UK, mucolytics such as carbocisteine and oral acetylcysteine are considered in NICE guidance for selected people with COPD and a chronic productive cough, rather than for everyone. That cautious positioning reflects the overall pattern of NAC's history: genuine but specific benefits, surrounded by broader claims that are harder to prove.

The 1970s breakthrough: paracetamol poisoning

The discovery that made NAC indispensable came from the problem of paracetamol overdose, which by the 1970s was one of the commonest causes of acute liver failure in Britain. Researchers had worked out that a small fraction of paracetamol is converted into a highly reactive metabolite, NAPQI. Normally glutathione neutralises it, but after an overdose glutathione stores are exhausted and NAPQI damages liver cells.

Early attempts to replenish thiol defences used cysteamine and methionine, but cysteamine in particular caused unpleasant side effects. A team in Edinburgh led by Laurie Prescott tested intravenous NAC instead and reported in The Lancet in 1977 that it protected the liver when given early after an overdose. Similar work with oral NAC followed in the United States and was summarised in a large multicentre analysis published in 1988.

The key lesson from these studies was timing. Treatment started within about eight hours of ingestion was associated with a very low rate of severe liver damage, while delays progressively reduced the benefit. This is why emergency departments plot blood paracetamol levels against time since ingestion on a treatment nomogram.

British practice continued to evolve. In 2012 the Medicines and Healthcare products Regulatory Agency simplified the approach so that a single, lower treatment line is used for all patients, and the traditional 21-hour intravenous regimen was later challenged by a shorter protocol studied in Scotland, which caused fewer adverse reactions. Treatment decisions remain strictly hospital-based.

New hopes and sobering trials

Once NAC was established as cheap, familiar and generally safe, researchers began testing it almost anywhere oxidative stress was thought to matter. The results illustrate how plausible mechanisms do not always translate into clinical benefit.

A striking example is contrast-induced kidney injury. A small German trial published in 2000 suggested that oral NAC protected kidney function in patients receiving contrast dye for CT scans, and the drug was quickly adopted in many hospitals. The large PRESERVE trial in 2018, involving several thousand patients, found no benefit, and routine use has since been abandoned.

Psychiatry has produced more intriguing signals. Because NAC influences glutamate signalling as well as glutathione, it has been tested in addiction, compulsive behaviours such as trichotillomania, bipolar depression and schizophrenia. Some trials were positive and others negative, and reviews generally describe the field as promising but not yet practice-changing.

Similar stories exist in idiopathic pulmonary fibrosis, where an early combination regimen including NAC was later found unhelpful, and in infertility and liver disease research. The overall picture is of a molecule whose safety makes it easy to trial, which is useful, but which also generates many small positive studies that larger trials do not confirm.

NAC as a supplement and in sport

Alongside its life as a medicine, NAC has long been sold as a food supplement in capsules, typically providing a few hundred milligrams per serving. In the UK it is available in this form, while licensed acetylcysteine for poisoning is a hospital medicine. In the United States, the FDA raised the question in 2020 of whether NAC could legally be a supplement given its earlier approval as a drug, before announcing enforcement discretion.

Athletes became interested because intense exercise generates reactive oxygen species that contribute to muscle fatigue. Laboratory and small human studies, including work on intravenous NAC during prolonged cycling, have shown that thiol donors can delay fatigue under specific conditions. Practical oral use is a different matter: effects have been small and inconsistent, and high doses often cause stomach upset.

There is also a theoretical concern that blunting oxidative signals too much might reduce some adaptations to training, a debate that applies to high-dose antioxidants generally. For most healthy people who train, evidence does not support routine NAC use for performance. Practical points worth knowing include:

• Common side effects at higher oral doses are nausea, bloating, diarrhoea and an unpleasant sulphurous smell.
• People with asthma should be cautious, especially with inhaled forms, because of the risk of bronchospasm.
• Anyone taking nitrates, anticoagulants or other regular medicines should speak to a pharmacist first.
• NAC is not on the World Anti-Doping Agency Prohibited List, but supplement contamination remains a risk, so batch-tested products are preferable for tested athletes.

The intravenous form used in hospitals can cause non-allergic anaphylactoid reactions such as flushing, rash and wheezing, which is one reason the shorter regimen was developed. These reactions are managed by clinical staff and are not relevant to oral supplements at ordinary doses.

Editorial conclusions

NAC's history shows how a modest chemical modification of an amino acid can produce a medicine with lasting value. Its role as the antidote to paracetamol poisoning, built largely on British research, has saved countless livers and lives.

Its other uses are more uneven. As a mucolytic it helps selected patients; in kidney protection it failed when properly tested; in psychiatry the jury is still out. That pattern is a useful reminder that a good safety record and an elegant mechanism are not substitutes for large, well-designed trials.

For people who train, NAC is best viewed as an interesting research compound rather than a proven performance aid. Diet, sleep and sensible programming matter far more than any antioxidant capsule.

If this topic interests you, our editorial team also suggests reading about how glutathione works in the body, how the liver handles common medicines and supplements, and which liver function tests are worth understanding.

References

1. Prescott LF, Park J, Ballantyne A, Adriaenssens P, Proudfoot AT. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet. 1977;2(8035):432–434.
2. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose: analysis of the national multicenter study (1976 to 1985). N Engl J Med. 1988;319(24):1557–1562.
3. Bateman DN, Dear JW, Thanacoody HK, et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet. 2014;383(9918):697–704.
4. Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343(3):180–184.
5. Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after angiography with sodium bicarbonate and acetylcysteine. N Engl J Med. 2018;378(7):603–614.
6. Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci. 2011;36(2):78–86.
7. Ferreira LF, Reid MB. Muscle-derived ROS and thiol regulation in muscle fatigue. J Appl Physiol. 2008;104(3):853–860.